SCHEMBL22729602

SCHEMBL22729602

COC1CCCCC1NC(=O)c1cn(C)c2c(C)cn(C)c(=O)c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
KDM4E B2RXH2 4/20 0.36
POLB P06746 2/20 0.36
USP2 O75604 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TAS1R3 Q7RTX0 2/20 0.35
TAS1R1 Q7RTX1 2/20 0.35
TAS1R2 Q8TE23 2/20 0.35
AXL P30530 6/20 0.35
MERTK Q12866 6/20 0.35
TYK2 P29597 2/20 0.34
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
MAPT P10636 1/20 0.33
CHRM1 P11229 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23116405 0.86 ALDH1A1 (0.40) ALDH1A1POLBUSP2NPSR1MEN1
SCHEMBL22729728 0.86 ALDH1A1 (0.40) ALDH1A1POLBUSP2NPSR1MEN1
SCHEMBL22729446 0.86 ALDH1A1 (0.40) ALDH1A1POLBUSP2NPSR1MEN1
SCHEMBL23116406 0.86 ALDH1A1 (0.40) ALDH1A1POLBUSP2NPSR1MEN1
SCHEMBL22729612 0.86 ALDH1A1 (0.40) ALDH1A1POLBUSP2NPSR1MEN1
SCHEMBL22729715 0.85 AXL (0.38) ALDH1A1AXLMERTK
SCHEMBL22754964 0.85 AXL (0.38) ALDH1A1AXLMERTK
SCHEMBL22729521 0.85 AXL (0.38) ALDH1A1AXLMERTK
SCHEMBL22754946 0.85 AXL (0.38) ALDH1A1AXLMERTK
SCHEMBL23139207 0.83 HDAC4 (0.39) ALDH1A1POLBUSP2NPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11459325-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-10-04 US disclosed
US-20210087186-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-25 US disclosed
US-20210087186-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-25 US disclosed
EP-3747885-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210087186-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC ALDH1A1 2626/4885KDM4E 1315/4885POLB 3952/4885
US-11459325-B2 Heterocyclic compound GBA1, GBA2, GALC ALDH1A1 2660/4885KDM4E 1270/4885POLB 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.